Your browser doesn't support javascript.
loading
Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease.
Kim, Daehong; Park, Giljun; Huuhtanen, Jani; Lundgren, Sofie; Khajuria, Rajiv K; Hurtado, Ana M; Muñoz-Calleja, Cecilia; Cardeñoso, Laura; Gómez-García de Soria, Valle; Chen-Liang, Tzu Hua; Eldfors, Samuli; Ellonen, Pekka; Hannula, Sari; Kankainen, Matti; Bruck, Oscar; Kreutzman, Anna; Salmenniemi, Urpu; Lönnberg, Tapio; Jerez, Andrés; Itälä-Remes, Maija; Myllymäki, Mikko; Keränen, Mikko A I; Mustjoki, Satu.
Afiliación
  • Kim D; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland.
  • Park G; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014, Helsinki, Finland.
  • Huuhtanen J; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland.
  • Lundgren S; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014, Helsinki, Finland.
  • Khajuria RK; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland.
  • Hurtado AM; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014, Helsinki, Finland.
  • Muñoz-Calleja C; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland.
  • Cardeñoso L; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014, Helsinki, Finland.
  • Gómez-García de Soria V; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland.
  • Chen-Liang TH; Hematology and Medical Oncology Department, Hospital Morales Meseguer. Centro Regional de Hemodonación, Universidad de Murcia, IMIB, 30008, Murcia, Spain.
  • Eldfors S; Department of Immunology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, 28006, Madrid, Spain.
  • Ellonen P; Department of Microbiology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, 28006, Madrid, Spain.
  • Hannula S; Department of Hematology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, 28006, Madrid, Spain.
  • Kankainen M; Hematology and Medical Oncology Department, Hospital Morales Meseguer. Centro Regional de Hemodonación, Universidad de Murcia, IMIB, 30008, Murcia, Spain.
  • Bruck O; Institute of Molecular Medicine Finland (FIMM), University of Helsinki, 00014, Helsinki, Finland.
  • Kreutzman A; Institute of Molecular Medicine Finland (FIMM), University of Helsinki, 00014, Helsinki, Finland.
  • Salmenniemi U; Institute of Molecular Medicine Finland (FIMM), University of Helsinki, 00014, Helsinki, Finland.
  • Lönnberg T; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland.
  • Jerez A; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014, Helsinki, Finland.
  • Itälä-Remes M; Department of Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, 00014, Helsinki, Finland.
  • Myllymäki M; iCAN Digital Precision Cancer Medicine, University of Helsinki and Helsinki University Hospital, 00014, Helsinki, Finland.
  • Keränen MAI; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290, Helsinki, Finland.
  • Mustjoki S; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014, Helsinki, Finland.
Nat Commun ; 11(1): 2246, 2020 05 07.
Article en En | MEDLINE | ID: mdl-32382059
ABSTRACT
Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD) carrying persistent CD4+ T cell clonal expansion harboring somatic mTOR, NFKB2, and TLR2 mutations. In the screening cohort (n = 134), we detect the mTOR P2229R kinase domain mutation in two additional cGvHD patients, but not in healthy or HSCT patients without cGvHD. Functional analyses of the mTOR mutation indicate a gain-of-function alteration and activation of both mTORC1 and mTORC2 signaling pathways, leading to increased cell proliferation and decreased apoptosis. Single-cell RNA sequencing and real-time impedance measurements support increased cytotoxicity of mutated CD4+ T cells. High throughput drug-sensitivity testing suggests that mutations induce resistance to mTOR inhibitors, but increase sensitivity for HSP90 inhibitors. Our findings imply that somatic mutations may contribute to aberrant T cell proliferations and persistent immune activation in cGvHD, thereby paving the way for targeted therapies.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T / Serina-Treonina Quinasas TOR / Enfermedad Injerto contra Huésped Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T / Serina-Treonina Quinasas TOR / Enfermedad Injerto contra Huésped Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article